Hot Features
Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Context Therapeutics Inc. (Nasdaq: CNTX) is a biopharmaceutical company advancing T cell engaging ("TCE") bispecific antibodies for solid tumors. Context is building an innovative portfolio of TCE bispecific therapeutics with multiple products in development, including two clinical-stage assets. Con... Context Therapeutics Inc. (Nasdaq: CNTX) is a biopharmaceutical company advancing T cell engaging ("TCE") bispecific antibodies for solid tumors. Context is building an innovative portfolio of TCE bispecific therapeutics with multiple products in development, including two clinical-stage assets. Context is headquartered in Philadelphia. Mehr anzeigen
CTIM-76 Phase 1 trial focused on CLDN6-positive gynecologic and testicular cancers Trial marks key milestone in driving pipeline progress PHILADELPHIA, Jan. 14, 2025 (GLOBE NEWSWIRE...
Mr. Pasternak brings decades of global pharmaceutical leadership experience Transition further highlights transformation of the Board to lead Context into next phase of growth PHILADELPHIA, Jan...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.0909 | -9.09 | 1 | 1.02 | 0.9 | 111178 | 0.94940725 | CS |
| 4 | -0.1909 | -17.3545454545 | 1.1 | 1.37 | 0.9 | 383871 | 1.06929935 | CS |
| 12 | -1.3809 | -60.3013100437 | 2.29 | 2.3257 | 0.9 | 549919 | 1.14724872 | CS |
| 26 | -1.5609 | -63.1943319838 | 2.47 | 2.75 | 0.9 | 370814 | 1.48259682 | CS |
| 52 | -0.0309 | -3.28723404255 | 0.94 | 2.75 | 0.9 | 385299 | 1.65684977 | CS |
| 156 | -1.2109 | -57.1179245283 | 2.12 | 2.79 | 0.47 | 405856 | 1.388155 | CS |
| 260 | -3.5309 | -79.5247747748 | 4.44 | 10.87 | 0.47 | 748455 | 3.60206613 | CS |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
